Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page’s displayed revision/version in the footer was updated from v3.5.2 to v3.5.3, indicating a technical update to the site interface rather than a change to the trial record.
    Difference
    0.0%
    Check dated 2026-04-25T18:45:41.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2; the previous revision v3.5.0 was removed.
    Difference
    0.0%
    Check dated 2026-04-18T13:36:20.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Added bibliographic entry: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer, J Clin Oncol, 2026 (online ahead of print).
    Difference
    0.0%
    Check dated 2026-04-04T05:51:32.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added Medullary thyroid carcinoma to the conditions list. Added a Resources section linking to the Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-03-28T01:52:45.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.0%
    Check dated 2026-03-20T22:24:38.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T17:54:33.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.